OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Barclays PLC

Barclays PLC grew its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 68.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 916,368 shares of the biotechnology company's stock after buying an additional 373,032 shares during the period. Barclays PLC owned 0.13% of OPKO Health worth $1,347,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in OPK. Cibc World Markets Corp bought a new position in OPKO Health during the 4th quarter worth approximately $45,000. Ieq Capital LLC acquired a new stake in shares of OPKO Health in the 4th quarter worth about $52,000. World Investment Advisors LLC bought a new stake in OPKO Health during the third quarter worth $61,000. Catalyst Funds Management Pty Ltd bought a new position in OPKO Health during the fourth quarter worth about $91,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of OPKO Health during the 4th quarter valued at $102,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased a total of 767,434 shares of company stock worth $1,238,312 over the last quarter. Corporate insiders own 49.69% of the company's stock.

OPKO Health Price Performance

OPK stock traded down $0.03 during midday trading on Friday, reaching $1.23. 1,251,238 shares of the company's stock traded hands, compared to its average volume of 3,873,984. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market cap of $975.46 million, a price-to-earnings ratio of -6.47 and a beta of 1.42. The company has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $1.56. OPKO Health, Inc. has a 1-year low of $1.19 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. The firm's revenue for the quarter was down 13.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. On average, analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

OPK has been the subject of several analyst reports. Barrington Research restated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating on the stock. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th. Finally, StockNews.com lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.